Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

ESMO-MCBS, early colon cancer, toxicity, adjuvant chemotherapy, quality of life

Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is used to grade therapies with curative intent. The study aimed to evaluate the applicability and reasonableness of the ESMO-MCBS scores in early colon cancer. Adjuvant studies were sourced f…

Sep 6^th • 17 mins read

A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure

value framework, European Society for Medical Oncology, Magnitude of Clinical Benefit Scale, American Society of Clinical Oncology, drug therapy, nasopharyngeal neoplasms

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) have developed frameworks to evaluate cancer treatments, particularly for nasopharyngeal carcinoma. A study compared these frameworks using data from 15 randomized controlled trials of systemic c…

Aug 12^th • 10 mins read

Leveraging existing data to contextualize phase II clinical trial findings in oncology

HER2, phase II trials, oncology, iDFS, EBC, early stage breast cancer

In the USA, over 250,000 women are diagnosed with early-stage breast cancer (EBC) yearly, with up to 30% having HER2 amplification. The standard care for HER2-positive EBC involves chemotherapy plus HER2-directed therapy for one year. The phase II Adjuvant Paclitaxel and Trastuzumab (APT) tr…

Sep 21^st • 3 mins read

Clinical Trials in Oncology and Defining Benefit

trials, oncology

The article emphasizes the importance of defining efficacy and futility in oncology clinical trials from the patient's perspective, highlighting that what may be effective for one patient could be futile for another. It advocates for precision oncology, which integrates improved efficacy markers wit…

Jan 22^nd • 1 min read